Raising capital with uncertainty

摘要: I study the effect of indirect ties between firm's scientific advisory board members and Food Drug Administration committees on underwriter prestige, underwriting fee, underpricing initial offering price range for firms pursuing highly uncertain opportunities. Prestigious underwriters compete to underwrite securities offered by connected regulator. This result in overpricing even though seeks enforce underpricing. The findings contribute Coase-Knight debate about role uncertainty firm boundaries.